Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Crohn´s Disease
Interventions
DRUG

Metronidazole

Metronidazole: 250 mg/8h. 3 months.

DRUG

Metronidazole

Metronidazole 250 mg/8h 3 months

DRUG

Azathioprine

Azathioprine: 2.5 mg/kg of weight/day. 3 months.

DRUG

Adalimumab

Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.

Trial Locations (22)

46026

Hospital Universitari i Policlinic La Fe, Valencia

Unknown

Hospital Germans Trias i Pujol, Badalona

Hospital de Bellvitge, Barcelona

Hospital del Mar, Barcelona

Hospital Parc Tauli, Sabadell

Hospital Mutua de Terrasa, Terrassa

Hospital General Dr. Negrín, Las Palmas de Gran Canaria

Hospital Puerto Real, Puerto Real

Hospital Reina Sofía, Córdoba

Hospital Arquitecto Marcide, Ferrol

Hospital de Fuenlabrada, Fuenlabrada

Hospital Clínico San Carlos, Madrid

Hospital Doce de Octubre, Madrid

Hospital Gregorio Marañón, Madrid

Hospital La Paz, Madrid

Hospital La Princesa, Madrid

Hospital Puerta de Hierro, Madrid

Hospital Ramón y Cajal, Madrid

Hospital Virgen de la Macarena, Seville

Hospital de Manises, Manises

Hospital Clínico, Valencia

Hospital Río Hortega, Valladolid

All Listed Sponsors
collaborator

Effice Servicios Para la Investigacion S.L.

INDUSTRY

lead

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

OTHER

NCT01564823 - Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease | Biotech Hunter | Biotech Hunter